CSPC Pharmaceutical Group announced FDA IND approval for SYS-6037, its mpox mRNA vaccine injection co-developed with the Institute of Microbiology of the Chinese Academy of Sciences. The clearance gives CSPC regulatory permission to begin U.S.-aligned clinical activity for the investigational candidate. An mRNA approach can enable rapid antigen updates, but in the near term the program’s clinical design will determine whether immunogenicity translates into durable protection against circulating mpox strains. The FDA IND milestone marks CSPC’s transition from preclinical and earlier preparation into a regulatory-executed clinical pathway. For investors, the update adds a publicly visible catalyst to CSPC’s pipeline and signals continued global interest in vaccine platforms for emerging infectious threats.